Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 10/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 6/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449476 | 0.77 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL3878154 | 0.73 | XDH (0.49) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL4439065 | 0.71 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL17802561 | 0.70 | CFTR (0.66) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL22583653 | 0.69 | FGFR1 (0.49) | — | |
| SCHEMBL2346678 | 0.67 | GSK3B (0.67) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL17354760 | 0.66 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| Hydrochloric Acid SCHEMBL29003046 | 0.65 | GSK3B (0.65) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL17354662 | 0.65 | ADORA2A (0.48) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27599134 | 0.65 | GSK3B (0.69) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0707479-A4 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0707479-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994026281-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1994-11-24 | — | — | WO | claimed |
| WO-2024081890-A2 | METHODS OF ASSESSING METABOLIC FLUX | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023225466-A2 | INHIBITING PURINE BIOSYNTHESIS TO INCREASE FAVIPIRAVIR POTENCY AGAINST RNA VIRUS INFECTIONS | VIRIOM, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220202803-A1 | COMBINATION THERAPIES INCLUDING INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE | CLEAR CREEK BIO INC (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220105120-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INOSINE MONOPHOSPHATE DEHYDROGENASE | CLEAR CREEK BIO INC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210115493-A1 | METHODS FOR DETERMINING A DRUG DOSING REGIMEN | Clear Creek Bio, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210113548-A1 | METHODS FOR DETERMINING A DRUG DOSING REGIMEN | Clear Creek Bio, Inc. | 2021-04-22 | — | — | US | disclosed |
| WO-2020219423-A1 | COMBINATION THERAPIES INCLUDING INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE | Clear Creek Bio, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020163412-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INOSINE MONOPHOSPHATE DEHYDROGENASE | Clear Creek Bio, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-0707479-A4 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5658890-A | INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0707479-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5405837-A | Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin | INDIANA UNIVERSITY FOUNDATION (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1995008994-A1 | ANTINEOPLASTIC COMBINATION OF TAXOL AND TIAZOFURIN | INDIANA UNIVERSITY FOUNDATION (US) | 1995-04-06 | — | — | WO | disclosed |
| WO-1994026281-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5358855-A | Inosinic acid dehydrogenase assay | THE MEDICAL COLLEGE OF PENNSYLVANIA (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1993023558-A1 | INOSINIC ACID DEHYDROGENASE ASSAY | THE MEDICAL COLLEGE OF PENNSYLVANIA (US) | 1993-11-25 | — | — | WO | disclosed |
| US-4446315-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1984-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115493-A1 | METHODS FOR DETERMINING A DRUG DOSING REGIMEN | CYP3A5, CYP2D6, CYP3A4 | PI4KA 4166/4885PI4K2B 4578/4885PI4K2A 4473/4885 |
| US-20220105120-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INOSINE MONOPHOSPHATE DEHYDROGENASE | IMPDH1, IMPDH2, ITPA | PI4KA 1868/4885PI4K2B 2419/4885PI4K2A 2365/4885 |
| US-20210113548-A1 | METHODS FOR DETERMINING A DRUG DOSING REGIMEN | CYP3A5, CYP2D6, CYP3A4 | PI4KA 4166/4885PI4K2B 4578/4885PI4K2A 4473/4885 |
| US-20220202803-A1 | COMBINATION THERAPIES INCLUDING INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DPYD, DLD | PI4KA 2579/4885PI4K2B 3152/4885PI4K2A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.